This potent NMDA receptor antagonist and experimental anticonvulsant (FW = 542.14 g/mol), also known as NVP-AAM077 and tetrasodium [[[(1S)-1-(4-bromophenyl)ethyl]amino](1,2,3,4-tetrahydro-2,3-dioxo-5- quinoxalinyl)methyl] phosphonate, is a competitive antagonist for ionotropic glutamate [N-methyl-D-aspartate] receptors (or GluN receptors). Although originally described as being 100x more active against GluN1/GluN2A receptors versus GluN1/GluN2B receptors, later studies revealed only a 5x difference in affinity. There is no difference in the steady-state levels of inhibition produced by NVP-AAM077 when it was either preapplied or coapplied with glutamate.
